PATENT CLAIM ANALYSIS

Application Number: 16025199
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-10
Patent Classification: ["514", "364000"]

Abstract:
This invention pertains to the use of fused bicycle heterocyclic adducts of thiohydroxy pyridines or pyrimidines as diacylglycerol O-acyltransferase 1 (DGAT-1) inhibitors to treat hyperlipidiemias and various diseases and disorders associated therewith. Other conditions also be ameliorated or avoided, such as high postprandial triglycerides or diet-related hypertriglyceridemia, cardiovascular risk associated with excessive triglycerides, and insulin resistance/glucose intolerance in overweight patients, those with diabetes or other glucose metabolic disorders such as Syndrome X and/or polycystic ovary disease.

Claim (Index 6):
A method of reducing food intake or adiposity comprising administering to a mammal a therapeutically effective amount of a compound according to  claim 1 , a pharmaceutical composition thereof or pharmaceutically acceptable salts of said compound, either alone or in combination with an anti-diabetic agent and/or an anti-obesity agent.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 95.0
- Lexical Diversity: 1.27273
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15151740', '13458452', '14628373', '15123791', '15866871']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7442220838529233
- 35 USC 102 Novelty (BERT): 0.5377384633553023
- Combined Prediction Score: 0.7235737218031613
- Mean Citation Score: 313.2950019999999
- Max Citation Score: 365.27896
- Similarity Product: 363.18222001138207

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test